Use of Liquid Biomarker Thymidine Kinase Activity (tka) to Predict Outcome and Progression in Patients with Metastatic Breast Cancer (MBC) in the GEICAM/2014-12 FLIPPER Trial.
Journal of Clinical Oncology(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined